Trials / Completed
CompletedNCT06485635
Real-life-persistence to Antifibrotic Treatments
Real-life-Persistence to Antifibrotic Treatments
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10,646 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment. Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | Nintedanib |
| DRUG | Pirfenidone | Pirfenidone |
Timeline
- Start date
- 2024-10-16
- Primary completion
- 2026-04-07
- Completion
- 2026-04-07
- First posted
- 2024-07-03
- Last updated
- 2026-04-15
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06485635. Inclusion in this directory is not an endorsement.